 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| amylin long acting (AZD6234) / AstraZeneca
Enrollment open, Trial primary completion date: APRICUS: A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity (clinicaltrials.gov) - Nov 5, 2024
P2, N=231, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2026 --> Oct 2025
- ||||| amylin long acting (AZD6234) / AstraZeneca
New P2 trial: APRICUS: A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity (clinicaltrials.gov) - Sep 20, 2024
P2, N=231, Not yet recruiting, Sponsor: AstraZeneca
- || amylin long acting (AZD6234) / AstraZeneca
Enrollment change: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese (clinicaltrials.gov) - Apr 24, 2024
P1, N=76, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2026 --> Oct 2025 N=40 --> 76
- || amylin long acting (AZD6234) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese (clinicaltrials.gov) - Mar 14, 2024
P1, N=40, Recruiting, Sponsor: AstraZeneca
N=40 --> 76 N=68 --> 40 | Trial completion date: Oct 2024 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Apr 2025
- ||| amylin long acting (AZD6234) / AstraZeneca
Trial completion: Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese (clinicaltrials.gov) - Dec 25, 2023
P1, N=54, Completed, Sponsor: AstraZeneca
N=68 --> 40 | Trial completion date: Oct 2024 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Apr 2025 Active, not recruiting --> Completed
- ||| amylin long acting (AZD6234) / AstraZeneca
Enrollment open: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese (clinicaltrials.gov) - Nov 27, 2023
P1, N=68, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || amylin long acting (AZD6234) / AstraZeneca
Enrollment closed: Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese (clinicaltrials.gov) - Nov 21, 2023
P1, N=54, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| amylin long acting (AZD6234) / AstraZeneca
New P1 trial: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese (clinicaltrials.gov) - Nov 15, 2023
P1, N=56, Not yet recruiting, Sponsor: AstraZeneca
- || amylin long acting (AZD6234) / AstraZeneca
Trial completion date, Trial primary completion date: Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese (clinicaltrials.gov) - Jan 12, 2023
P1, N=64, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
- ||| amylin long acting (AZD6234) / AstraZeneca
Enrollment open: Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese (clinicaltrials.gov) - Oct 20, 2022
P1, N=64, Recruiting, Sponsor: AstraZeneca
Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023 Not yet recruiting --> Recruiting
- ||| amylin long acting (AZD6234) / AstraZeneca
New P1 trial: Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese (clinicaltrials.gov) - Aug 22, 2022
P1, N=64, Not yet recruiting, Sponsor: AstraZeneca